Loading clinical trials...

Glofitamab in Chinese Patients With R/R DLBCL | Clinical Trials | Clareo Health

RECRUITING

Glofitamab in Chinese Patients With R/R DLBCL

A Study to Evaluate Glofitamab as Single Agent in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT06481826•Peking Union Medical College Hospital

View on ClinicalTrials.gov

Summary

This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Histologically-confirmed DLBCL
•2. Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy
•3. Participants must have measurable disease

Exclusion Criteria

•1. Pregnancy or breastfeeding
•2. Patient with known active infection, or reactivation of a latent infection
•3. Patient with active autoimmune disease or immune deficiency
•4. severe organ failure：LVEF\<40%；DLCO\<40%；eGFR\<30ml/min；Bilirubin≥3ULN
•5. Patients who are dependent on the sponsor, the investigator or the trial site

Locations (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

January 1, 2024

Primary Completion Date

December 31, 2027

Completion Date

December 31, 2028

Last Updated

July 1, 2024

Enrollment

ESTIMATED participants

Conditions

DLBCL - Diffuse Large B Cell Lymphoma

Interventions

Glofitamab

DRUG

Contacts

Jing Ruan

CONTACT

+8615201435860 15201435860@163.com

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

NCT07255963

DLBCL - Diffuse Large B Cell Lymphoma

View study

RECRUITINGNA

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

NCT05940272

Lymphoma, B-CellLymphoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 1, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Glofitamab in Chinese Patients With R/R DLBCL

Inclusion Criteria

Exclusion Criteria

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Real-World Study of DLBCL With Different Genetic Subtypes

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL

AZA Combined with R-GemOx for Elderly DLBCL Patients